William Hark, MD
Allergy · Richmond, VANPI 1891708665
Payments from drug & device makers
What this record shows
This record is dominated by other: $734,012 of the $945,272 with a category attached, or 77.7%. Kaleo, Inc. accounts for 98.6% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $713,970 and has fallen 99.6% since, to $2,668 in 2025. Among allergy clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 736 payments — averaging $1284.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaleo, Inc.$932K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Sanofi$1K
- Genentech USA, Inc.$989
- plus $6K from 29 others
What the payments were for
- Food & beverage$13,6331%
- Education$760%
- Ownership interest$197,55121%
- Other$734,01278%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaleo, Inc. | 40 | $932,154 |
| AstraZeneca | 88 | $2,337 |
| Regeneron Healthcare Solutions, Inc. | 65 | $1,248 |
| GSK | 94 | $1,163 |
| Sanofi | 54 | $1,101 |
| Genentech USA, Inc. | 67 | $989 |
| Amgen | 36 | $880 |
| Optinose US, Inc. | 48 | $748 |
| Novartis | 39 | $746 |
| CSL Behring | 33 | $596 |
| Grifols USA, LLC | 26 | $542 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $484 |
| Biocryst US Sales Co., LLC | 15 | $316 |
| Pfizer | 19 | $295 |
| ARS Pharmaceuticals Operations, Inc. | 16 | $279 |
| Blueprint Medicines Corporation | 10 | $269 |
| Boehringer Ingelheim | 11 | $171 |
| Pharming Healthcare, Inc. | 9 | $143 |
| Teva Pharmaceuticals USA, Inc. | 9 | $132 |
| Incyte Corporation | 5 | $128 |
| Aimmune Therapeutics, Inc. | 6 | $103 |
| Alk-abello, Inc | 4 | $71 |
| Greer Laboratories, Inc. | 3 | $51 |
| Organon | 3 | $51 |
| Covis Pharma GmbH | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Phadia US Inc. | 2 | $35 |
| AbbVie | 2 | $31 |
| Mylan Pharmaceuticals Inc. | 2 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Merck | 1 | $14 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$945,272 in reported general payments places this provider in the 90th percentile of 26 allergy providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $121,581 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,038 |
| Epinephrine | 59 | $9,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,553 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $5,297 |
| Azelastine Hcl | 144 | $4,182 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $4,159 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 33 | $3,727 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $3,276 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,259 |
| Montelukast Sodium | 219 | $2,365 |
| Desloratadine | 16 | $1,962 |
| Ipratropium Bromide | 37 | $1,349 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,246 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $596 | $121,58113 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $1,163 | $23,59236 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $9,75359 claims |
| AstraZenecaSymbicort | $2,337 | $3,25914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 26 allergy providers in Virginia.
Other allergy in Richmond
- Lawrence GelberRichmond$1.9M
- Robert CallRichmond$1.9M
- Muhammad RaisRichmond$16K
- Zeeshan KhakwaniRichmond$8K
- Kimberly GeorgeRichmond$2K
- Thomas Platts MillsCharlottesville$35K
- Kelly MaplesNorfolk$26K
- Jaimin PatelHenrico$14K
- Sarah SprietFort Belvoir$9K
- Laura IspasLeesburg$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.